Type 2 & other diabetes

Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial

LancetPublished Cluster-randomised controlled trial

Primary result · Blood pressure or fasting glucose control (hypertension or diabetes)Result — go to the resultAdjusted risk difference 1.80 95% CI −4.52 to 8.12

Authors' conclusion

In sub-Saharan Africa, integrated community care could reach a high standard of care for people with diabetes or hypertension without adversely affecting outcomes for people with HIV.

Study context

Population
Adults ≥18 years with HIV, T2D or hypertension (or a combination), clinically stable, in regular care ≥6 months, 14 primary care facilities in Tanzania and Uganda124 groups
Participants
1,864 adults
Comparison
Integrated community-based care vs integrated facility-based care
  • Community caren = 62 groups
  • Facility caren = 62 groupsreference
Primary endpoint
Coprimary: (1) composite of blood pressure (<140/90 mm Hg) or fasting glucose (<7.0 mmol/L) control in those with hypertension and/or diabetes; (2) viral load suppression (<1000 copies per mL or undetectable) in those with HIV alone
Follow-up
12 months
Methodological detailsopen-label, multicountry
  • Open-label
  • Multicountry

Primary result

As reported in the abstract

Blood pressure or fasting glucose control (hypertension or diabetes)

Adjusted risk difference

1.80

95% CI −4.52 to 8.12

P = 0.58

Events by treatment group

Community carevs Facility care
adjusted risk difference 1.80 (95% CI −4.52 to 8.12); P = 0.58

Further findings

OutcomeCommunity careFacility careAdjusted risk difference (CI)P value
Viral load suppression (HIV alone; coprimary) · 12 monthsIntention-to-treat · non-inferiority99.1%98.7%0.44 (−1.12 to 1.99)P for non-inferiority < 0.0001

Events

OutcomeCommunity careFacility care
Deaths77

Original publication

Integrated community-based versus facility-based care for people with HIV, diabetes, and hypertension in sub-Saharan Africa (INTE-COMM): an open-label, multicountry, cluster-randomised trial. Lancet. Published 14 March 2026. doi:10.1016/s0140-6736(25)02641-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.